Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Fluoxetine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 known ✓ | P31645 | 11/20 | 1.00 |
| ▸ | MEN1 | O00255 | 4/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 4/20 | 1.00 |
| ▸ | LMNA | P02545 | 4/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 4/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 1.00 |
| ▸ | NPC1 | O15118 | 2/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 2/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 2/20 | 1.00 |
| ▸ | MTOR | P42345 | 2/20 | 1.00 |
| ▸ | RAB9A | P51151 | 2/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 1.00 |
| ▸ | HTR2C | P28335 | 2/20 | 1.00 |
| ▸ | KCNK2 | O95069 | 2/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 2/20 | 1.00 |
| ▸ | CACNA1C | Q13936 | 2/20 | 1.00 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 1.00 |
| ▸ | TP53 | P04637 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| R-Fluoxetine SCHEMBL1200433 | 1.00 | SLC6A4 (1.00) | SLC6A4MEN1KMT2ALMNASLC6A2 | |
| Fluoxetine SCHEMBL8467346 | 1.00 | SLC6A4 (1.00) | SLC6A4MEN1KMT2ALMNASLC6A2 | |
| Fluoxetine SCHEMBL570572 | 1.00 | SLC6A4 (1.00) | SLC6A4MEN1KMT2ALMNASLC6A2 | |
| Fluoxetine SCHEMBL8353 | 1.00 | SLC6A4 (1.00) | SLC6A4MEN1KMT2ALMNASLC6A2 | |
| R-Fluoxetine SCHEMBL3905325 | 0.99 | SLC6A4 (1.00) | SLC6A4MEN1KMT2ALMNASLC6A2 | |
| Fluoxetine SCHEMBL7081402 | 0.99 | SLC6A4 (1.00) | SLC6A4MEN1KMT2ALMNASLC6A2 | |
| Fluoxetine SCHEMBL8911991 | 0.99 | SLC6A4 (1.00) | SLC6A4MEN1KMT2ALMNASLC6A2 | |
| Fluoxetine SCHEMBL17436534 | 0.99 | SLC6A4 (0.97) | SLC6A4MEN1KMT2ALMNASLC6A2 | |
| Fluoxetine SCHEMBL3399076 | 0.99 | SLC6A4 (1.00) | SLC6A4MEN1KMT2ALMNASLC6A2 | |
| Fluoxetine SCHEMBL7902048 | 0.99 | SLC6A4 (0.97) | SLC6A4MEN1KMT2ALMNASLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 7218 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250382291-A1 | SUBSTITUTED PYRROLO[2,3-b]PYRIDINES FOR SUPPRESSING TOXIC ENDOPLASMIC RETICULUM STRESS | UNIV COLUMBIA (US) | 2025-12-18 | — | — | US | claimed |
| EP-4566590-A1 | TASTE-MASKING MICROSPHERE, PREPARATION PROCESS THEREFOR, AND USE THEREOF | Harbin Kanon Pharmaceutical Co., Ltd (CN) | 2025-06-11 | — | — | EP | claimed |
| US-12227500-B2 | Substituted pyrrolo[2,3-b]pyridines for suppressing toxic endoplasmic reticulum stress | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2025-02-18 | — | — | US | claimed |
| WO-2025024501-A1 | NEUROMODULATORY PEPTIDES | LACTOCORE, INC. (US) | 2025-01-30 | — | — | WO | claimed |
| EP-3375452-B1 | USE OF LAMBDA INTERFERONS IN THE TREATMENT OF AN OBESITY-RELATED DISORDER, ATHEROSCLEROSIS OR A COAGULATION DISORDER | ANDREAKOS EVANGELOS (GR) | 2025-01-08 | — | — | EP | claimed |
| CN-116655475-B | Preparation method of fluoxetine hydrochloride | 山东轩鸿生物医药有限公司 | 2024-12-31 | — | — | CN | claimed |
| CN-113573723-B | Synthetic neuromodulatory peptides | 拉托科公司 | 2024-12-03 | — | — | CN | claimed |
| CN-113286777-B | Compounds, compositions and methods for modulating iron death and treating excitotoxic disorders | 纽约市哥伦比亚大学理事会 | 2024-10-29 | — | — | CN | claimed |
| US-12121564-B2 | Use of lambda interferons in the treatment of obesity-related disorders and related diseases | BIOMEDICAL RESEARCH FOUNDATION OF THE ACADEMY OF ATHENS (GR) | 2024-10-22 | — | — | US | claimed |
| WO-2024189252-A1 | 2-HYDROXY-OCTADECENE-9-CIS-OATE FOR USE IN THE TREATMENT OF ONCOLOGICAL PATHOLOGIES AND NEUROPATHIC PAIN | LAMINAR PHARMACEUTICALS S.A. (ES) | 2024-09-19 | — | — | WO | claimed |
| EP-0391070-A1 | Process for the preparation of N-methyl-3-(p-trifluoro-methylphenoxy)-3-phenyl-propylamine and their salts | ORION-YHTYMÄ OY FERMION (FI) | 1990-10-10 | — | — | EP | claimed |
| EP-0380924-A1 | Process for the preparation of fluoxetine hydrochloride | Magnone, Grato (IT) | 1990-08-08 | — | — | EP | claimed |
| EP-0123469-B1 | USE OF FLUOXETINE FOR THE MANUFACTURE OF AN ANTI-ANXIETY AGENT | ELI LILLY AND COMPANY (US) | 1987-11-25 | — | — | EP | claimed |
| US-4683235-A | CODEINE AND (NOR)FLUOXETINE | ELI LILLY AND COMPANY (US) | 1987-07-28 | — | — | US | claimed |
| US-4647591-A | Method for improving memory | ELI LILLY AND COMPANY (US) | 1987-03-03 | — | — | US | claimed |
| EP-0193354-A2 | Analgesic composition | ELI LILLY AND COMPANY (US) | 1986-09-03 | — | — | EP | claimed |
| EP-0193355-A2 | Analgesic composition | ELI LILLY AND COMPANY (US) | 1986-09-03 | — | — | EP | claimed |
| US-4594358-A | Administering (nor)floxetine before dextropropoxyphene | ELI LILLY AND COMPANY (US) | 1986-06-10 | — | — | US | claimed |
| EP-0123469-A1 | Use of fluoxetine for the manufacture of an anti-anxiety agent | ELI LILLY AND COMPANY (US) | 1984-10-31 | — | — | EP | claimed |
| US-4329356-A | Treatment of hypertension with fluoxetine and l-5-hydroxytryptophane | ELI LILLY AND COMPANY (US) | 1982-05-11 | — | — | US | claimed |